683 Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

683 Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.4M	Sell	107,500 -20,600	-16%	-$6.21M	1.59%	17
2026 Q1	$42.4M	Sell	128,100 -13,000	-9%	-$4.42M	2.21%	7
2025 Q4	$56.1M	Buy	141,100 +5,400	+4%	+$2.39M	2.44%	9
2025 Q3	$61.9M	Sell	135,700 -5,600	-4%	-$2.28M	3.23%	7
2025 Q2	$46.1M	Buy	141,300 +90,100	+176%	+$24.9M	3.03%	7
2025 Q1	$13.8M	Sell	51,200 -7,500	-13%	-$1.93M	0.95%	30
2024 Q4	$13.8M	Sell	58,700 -64,600	-52%	-$17M	0.86%	32
2024 Q3	$33.9M	Buy	123,300 +400	+0.3%	+$104K	2.58%	9
2024 Q2	$29.9M	Buy	122,900 +87,100	+243%	+$13.8M	2.26%	10
2024 Q1	$5.35M	Buy	+35,800	New	+$5.97M	0.39%	54
2023 Q4	–	Sell	-10,000	Closed	-$1.77M	–	260
2023 Q3	$1.77M	Buy	+10,000	New	+$1.91M	0.14%	87

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's ALNY Position: Q2 2026 in Review

683 Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 67% in Q2 2026, buying an estimated $4.22M and bringing the position to 35,000 shares worth $10.5M. The position accounts for 0.52% of the portfolio, ranked #46.

683 Capital Management first reported a position in ALNY in Q3 2016 and has held it in 27 quarters since. The position peaked at $30.5M in Q1 2019. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

683 Capital Management held 35,000 shares of Alnylam Pharmaceuticals worth $10.5M as of Q2 2026.
683 Capital Management bought 14,000 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $4.22M.
Alnylam Pharmaceuticals made up 0.52% of 683 Capital Management's portfolio in Q2 2026, its #46 holding.
683 Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2016 and has held it in 27 quarters since.
683 Capital Management's Alnylam Pharmaceuticals position peaked at $30.5M in Q1 2019.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.